{
  "id": 149027,
  "title": "Pancreatic Cancer Vaccine Shows Interception Promise in High-Risk Patients",
  "url": "https://urgent.news/2026/08/04/pancreatic-cancer-vaccine-shows-interception-promise-in-high-risk",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-04T21:05:10.000Z",
  "source": {
    "name": "MedPage Today",
    "slug": "medpage-today",
    "url": "https://www.medpagetoday.com/hematologyoncology/othercancers/122487"
  },
  "original_language": "en",
  "account": "A peptide vaccine targeting KRAS mutations in pancreatic cancer demonstrated promising results in a small study of high-risk patients. The vaccine stimulated KRAS-specific T-cell responses in 18 out of 20 patients with mutations linked to pancreatic ductal adenocarcinoma (PDAC). The immune cell responses persisted for up to 2 years after vaccination, and no patient developed pancreatic cancer during the 16.5-month follow-up period. No severe adverse events were reported. The findings support further investigation of the vaccine for preventing PDAC in high-risk individuals, reported Neeha Zaidi, MD, from Johns Hopkins Medicine and colleagues in Cancer Discovery. While the immune response was observed in the blood, the study did not investigate whether the immune cells reached the pancreatic tissue. The researchers plan to continue monitoring high-risk patients with pancreatic cysts or intraductal papillary mucinous neoplasms (IPMN) who undergo surgery, aiming to assess both blood and tissue-level effects of vaccination.",
  "summary": "(MedPage Today) -- A peptide vaccine targeting KRAS mutations in pancreatic cancer showed preliminary evidence of activity in a small study of high-risk patients. The vaccine elicited KRAS-specific T-cell responses in 18 of 20 patients with mutations...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}